ES2505643T3 - Galectina para uso en el tratamiento del síndrome del ojo seco - Google Patents

Galectina para uso en el tratamiento del síndrome del ojo seco Download PDF

Info

Publication number
ES2505643T3
ES2505643T3 ES06758319.5T ES06758319T ES2505643T3 ES 2505643 T3 ES2505643 T3 ES 2505643T3 ES 06758319 T ES06758319 T ES 06758319T ES 2505643 T3 ES2505643 T3 ES 2505643T3
Authority
ES
Spain
Prior art keywords
treatment
dry eye
galectin
eye syndrome
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06758319.5T
Other languages
English (en)
Inventor
Noorjahan Panjwani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tufts University
Original Assignee
Tufts University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts University filed Critical Tufts University
Application granted granted Critical
Publication of ES2505643T3 publication Critical patent/ES2505643T3/es
Anticipated expiration legal-status Critical
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1732—Lectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Una composición para su uso en el tratamiento o en la prevencion del ojo seco en un mamifero que necesite dicho tratamiento o prevencion, y ditha composición comprende una cantidad terapeuticamente eficaz de una proteina galectina.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30
imagen31
imagen32
imagen33
imagen34
imagen35
imagen36
imagen37
imagen38
imagen39
imagen40
imagen41
imagen42
imagen43
imagen44
imagen45
imagen46
imagen47
imagen48
imagen49
imagen50
imagen51
imagen52
imagen53
imagen54
imagen55
imagen56
imagen57
imagen58
imagen59
imagen60
imagen61
imagen62
imagen63
imagen64
imagen65
imagen66
imagen67
imagen68
imagen69
imagen70

Claims (1)

  1. imagen1
    imagen2
    imagen3
    imagen4
ES06758319.5T 2005-04-13 2006-04-13 Galectina para uso en el tratamiento del síndrome del ojo seco Active ES2505643T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/104,677 US7189697B2 (en) 2004-04-13 2005-04-13 Compositions and uses of a galectin for treatment of dry eye syndrome
US104677 2005-04-13
PCT/US2006/013785 WO2006113311A2 (en) 2005-04-13 2006-04-13 Compositions and uses of a galectin for treatment of dry eye syndrome

Publications (1)

Publication Number Publication Date
ES2505643T3 true ES2505643T3 (es) 2014-10-10

Family

ID=37115683

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06758319.5T Active ES2505643T3 (es) 2005-04-13 2006-04-13 Galectina para uso en el tratamiento del síndrome del ojo seco

Country Status (9)

Country Link
US (1) US7189697B2 (es)
EP (1) EP1874337B1 (es)
JP (1) JP5146835B2 (es)
KR (2) KR20140054347A (es)
CN (1) CN101500589B (es)
CA (1) CA2604583C (es)
ES (1) ES2505643T3 (es)
MX (1) MX2007012725A (es)
WO (1) WO2006113311A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6967021B2 (en) * 2001-04-27 2005-11-22 Trustees Of Tufts College Use of Galectin-3 to promote the re-epithelialization of wounds
US20070185014A1 (en) * 2006-02-09 2007-08-09 The Schepens Eye Research Institute, Inc. Methods and compositions for modulating conjunctival goblet cells
CA2638823A1 (en) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in the process of bone remodeling
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
WO2008036717A2 (en) * 2006-09-19 2008-03-27 Emory University Use of soluble galectin-3 (gal-3) for cancer treatment
GB0622694D0 (en) * 2006-11-14 2006-12-27 Serentis Ltd Use of opioid compounds in wound healing
DE112008001228T5 (de) 2007-05-04 2010-03-18 Abbott Medical Optics Inc., Santa Ana Verfahren und Vorrichtungen zum Messen von einem Tränenfilm und zum Diagnostizieren von Tränenfehlfunktionen
CA2797347C (en) 2009-04-28 2016-11-01 Joseph W. Sassani Methods and compositions for treating dry eye
US20110065643A1 (en) * 2009-06-12 2011-03-17 University Of Southern California Clusterin Pharmaceuticals and Treatment Methods Using the Same
CN104024227B8 (zh) 2011-07-22 2025-07-29 北京贝美拓新药研发有限公司 抑制脯氨酸羟化酶活性的化合物的晶型及其应用
US9636355B2 (en) 2011-09-22 2017-05-02 Theo Holdings, Llc Hypertonic dextran solution and methods of treating and preventing recurrent corneal erosion
US20150237837A1 (en) * 2012-06-18 2015-08-27 Duke University Non-Human Model for Wound Healing
ES2723885T3 (es) 2012-07-19 2019-09-03 Daiichi Sankyo Co Ltd Anticuerpos anti-Siglec-15
KR20160091836A (ko) * 2015-01-26 2016-08-03 주식회사 바이오코즈글로벌코리아 뉴레귤린을 포함하는 상처 또는 안구건조증의 치료용 약학 조성물
WO2017160884A1 (en) * 2016-03-14 2017-09-21 Capricor, Inc. Methods of treating ocular inflammation and chemical injuries of the eye with extracellular vesicles
US10456447B2 (en) * 2016-10-05 2019-10-29 Consejo Nacional de Investigacions Cientificas y Técnicas Therapeutic modulation of skin immune system with Gal-7
CA3101988A1 (en) * 2018-06-07 2019-12-12 Palleon Pharmaceuticals Inc. Multimeric proteins for detecting a carbohydrate and/or treating a siglec-mediated disorder

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3058920B2 (ja) * 1996-04-19 2000-07-04 一男 坪田 アルブミンを有効成分とする医薬組成物
US5869289A (en) * 1996-10-09 1999-02-09 Incyte Pharmaceuticals, Inc. Human galectin homolog
WO1999012041A1 (en) * 1997-09-05 1999-03-11 The Board Of Regents Of The University Of Oklahoma Composition and methods using galectin-1
AU2001243622A1 (en) * 2000-03-13 2001-09-24 La Jolla Institute For Allergy And Immunology Monocyte chemoattractant activity of galectin-3
US6967021B2 (en) * 2001-04-27 2005-11-22 Trustees Of Tufts College Use of Galectin-3 to promote the re-epithelialization of wounds
US6770622B2 (en) * 2001-06-08 2004-08-03 Gary A. Jarvis N-terminally truncated galectin-3 for use in treating cancer
JP2005505592A (ja) * 2001-10-11 2005-02-24 アルコン，インコーポレイテッド 抗炎症性ステロイドとｍｕｃ−１分泌促進薬との組み合わせによる、ドライアイを処置するための方法

Also Published As

Publication number Publication date
KR20140054347A (ko) 2014-05-08
CA2604583C (en) 2015-06-02
CN101500589B (zh) 2014-06-18
EP1874337A2 (en) 2008-01-09
JP2008536857A (ja) 2008-09-11
KR20070119030A (ko) 2007-12-18
CN101500589A (zh) 2009-08-05
US20060189514A1 (en) 2006-08-24
EP1874337A4 (en) 2010-07-14
WO2006113311A2 (en) 2006-10-26
MX2007012725A (es) 2008-04-09
US7189697B2 (en) 2007-03-13
KR101589742B1 (ko) 2016-01-28
WO2006113311A3 (en) 2009-04-16
JP5146835B2 (ja) 2013-02-20
EP1874337B1 (en) 2014-09-03
CA2604583A1 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
ES2505643T3 (es) Galectina para uso en el tratamiento del síndrome del ojo seco
ES2665917T3 (es) Endoxifeno para su uso en el tratamiento del cáncer
ES2526521T3 (es) Composiciones de antibiótico para el tratamiento del oído
JP2023116721A5 (es)
ES2502472T3 (es) Composición adhesiva para su uso en un inmunosensor
ES2575152T3 (es) Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores
CL2012000518A1 (es) Uso de un anticuerpo aislado o fragmento de enlace antígeno del mismo que comprende una región variable de cadena ligera y una de cadena pesada (sec nº38 y nº40) útil en el tratamiento y prevención de mieloma en un mamífero (div. sol. 3615-07).
ES2515168T3 (es) Detección y tratamiento de la esquizofrenia
BRPI0717845A2 (pt) Uso de compostos, composições farmacêuticas e métodos para o tratamento e/ou profilaxia de enfermidades que podem ser tratadas com agentes de elevação de colesterol-hdl e compostos
ECSP056229A (es) Una composición farmacéutica que comprende formas polimórficas de 3-(4-amino-1-oxo-1.3 dyhidro-isoindol-2-il)-piperidina-2,6-diona para el tratamiento y manejo de cánceres
ES2603963T3 (es) Composiciones y métodos para el tratamiento de trastornos renales
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
CL2007003552A1 (es) Compuestos derivados de pirimidina y piridina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de un trastorno proliferativo celular.
CL2008001656A1 (es) Anticuerpo anti-c3b; composicion farmaceutica que lo comprende, y su uso para prevenir o tratar un trastorno asociado con el complemento; kit que lo contiene.
CL2008000795A1 (es) Uso de 1-[2-(2,4-dimetilfenilsulfanil)fenil)piperazina para el tratamiento del dolor o de los sintomas residuales de la depresion; y dicho compuesto.
AR054094A1 (es) Tratamientos de cancer
AR045179A1 (es) Uso de una combinacion de un inhibidor de la quinasa del receptor del factor de crecimiento epidermico y de agentes citotoxicos para el tratamiento e inhibicion del cancer
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
CL2007002494A1 (es) Composicion farmaceutica que comprende una pirimidina trisustituida en combinacion con un compuesto con propiedades inhibitorias de pde5; y uso en el tratamiento de una enfermedad que involucre vasoconstriccion.
AR028355A1 (es) Compuestos para el tratamiento de la fibromialgia y el sindrome de fatiga cronica
EP1602971A4 (en) LIGHT SOURCE AND PROJECTOR THEREOF
JP2022122912A5 (es)
ES2534911T3 (es) Uso de plasmina para el tratamiento de fallo de filtración después de trabeculectomía
JP2023175831A5 (es)
AR057643A1 (es) Lacosamida para terapia adjunta